CN116326782A - Protein calcium and preparation method thereof - Google Patents
Protein calcium and preparation method thereof Download PDFInfo
- Publication number
- CN116326782A CN116326782A CN202310334569.0A CN202310334569A CN116326782A CN 116326782 A CN116326782 A CN 116326782A CN 202310334569 A CN202310334569 A CN 202310334569A CN 116326782 A CN116326782 A CN 116326782A
- Authority
- CN
- China
- Prior art keywords
- calcium
- solution
- protein
- lactalbumin
- citrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 76
- 239000011575 calcium Substances 0.000 title claims abstract description 75
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 74
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000000243 solution Substances 0.000 claims abstract description 35
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims abstract description 27
- 235000018102 proteins Nutrition 0.000 claims abstract description 26
- 239000001354 calcium citrate Substances 0.000 claims abstract description 23
- 235000013337 tricalcium citrate Nutrition 0.000 claims abstract description 23
- 239000000843 powder Substances 0.000 claims abstract description 19
- 102000004407 Lactalbumin Human genes 0.000 claims abstract description 15
- 108090000942 Lactalbumin Proteins 0.000 claims abstract description 15
- 239000012460 protein solution Substances 0.000 claims abstract description 15
- 235000021241 α-lactalbumin Nutrition 0.000 claims abstract description 15
- 239000000725 suspension Substances 0.000 claims abstract description 13
- 238000003756 stirring Methods 0.000 claims abstract description 11
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims abstract description 6
- 238000005303 weighing Methods 0.000 claims abstract description 3
- 229960005069 calcium Drugs 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 11
- MKJXYGKVIBWPFZ-CEOVSRFSSA-L calcium;(2s)-2-hydroxypropanoate Chemical compound [Ca+2].C[C@H](O)C([O-])=O.C[C@H](O)C([O-])=O MKJXYGKVIBWPFZ-CEOVSRFSSA-L 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 3
- 239000001527 calcium lactate Substances 0.000 claims description 3
- 229960002401 calcium lactate Drugs 0.000 claims description 3
- 235000011086 calcium lactate Nutrition 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical group [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract description 3
- 229910001424 calcium ion Inorganic materials 0.000 abstract description 2
- 238000002525 ultrasonication Methods 0.000 abstract description 2
- 239000002245 particle Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 6
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 2
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000032798 delamination Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 235000021075 protein intake Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000004686 pentahydrates Chemical class 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种蛋白钙及其制备方法,将α‑乳白蛋白溶解,配制蛋白溶液;称取可溶性钙盐,配制钙溶液;蛋白液与钙溶液混合,搅拌,形成含有结合钙的蛋白钙溶液;称取柠檬酸钙,加入上述反应液,搅拌、超声,使柠檬酸钙分散更充分,形成混悬液;喷雾干燥,制备成粉。发明选择出一种既能够包裹住不溶性钙,又同时能与钙离子结合的蛋白,并且制作步骤相对简单,使得生产方案和产物能够落地;达到了提高产品含钙量,以及平缓钙的吸收利用的两方面的效果。
The invention discloses protein calcium and a preparation method thereof. Alpha-lactalbumin is dissolved to prepare protein solution; soluble calcium salt is weighed to prepare calcium solution; protein solution and calcium solution are mixed and stirred to form protein calcium containing bound calcium solution; weighing calcium citrate, adding the above reaction solution, stirring and ultrasonication, so that the calcium citrate is more fully dispersed to form a suspension; spray-dried to prepare a powder. The invention selects a protein that can not only wrap insoluble calcium, but also combine with calcium ions, and the production steps are relatively simple, so that the production plan and products can be implemented; the calcium content of the product is increased, and the absorption and utilization of calcium is smooth two-sided effects.
Description
技术领域technical field
本发明涉及一种蛋白钙及其制备方法,特别涉及蛋白结合钙与包埋游离钙The invention relates to protein calcium and its preparation method, in particular to protein-bound calcium and embedded free calcium
背景技术Background technique
钙的摄入情况对维持儿童/青少年正常骨密度、达到高骨量峰值、减少骨折和降低老年骨质疏松风险至关重要。现阶段由于人体中钙的缺乏,钙制剂的研究开发越来越受到人们的关注与重视。Calcium intake is critical for maintaining normal bone density in children/adolescents, achieving high peak bone mass, reducing fractures, and reducing the risk of osteoporosis in old age. Due to the lack of calcium in the human body at this stage, the research and development of calcium preparations has attracted more and more people's attention and attention.
现在补钙的同时增加蛋白质的摄入量会对骨组织生长起到正相关作用,但补钙的同时摄入充足的蛋白质才对骨骼有良好的改善效果。对于含钙量低的原料,若要摄入相同量的钙元素则需要更大剂量。At present, increasing protein intake while supplementing calcium will have a positive correlation effect on the growth of bone tissue, but sufficient protein intake while supplementing calcium will have a good effect on bone improvement. For raw materials with low calcium content, a larger dose is required to consume the same amount of calcium element.
中国发明申请专利(CN201510094700.6)公开的“一种基于难溶性钙和食源性蛋白复合物的新型钙增强剂及其制备和表征方法”,该法将食源性蛋白配制成溶液,难溶性钙分散在水中形成悬浮液,再按照蛋白和难溶性钙的质量比2:1~1:200混合,通过离心或静置将反应结束后的混合液分离,得到的沉淀漂洗、再分散,进行喷雾干燥或冷冻干燥处理,得到难溶性钙-蛋白复合粉末。该方法避免了额外添加稳定剂来稳定不溶性钙盐而造成的产品口感差和制备成本高等问题,但无法满足蛋白结合钙的高利用,高吸收;更无法达到钙源的逐步释放的效果。本发明的目的在于克服现有技术的不足,开发一种原料安全、性能稳定、含钙量高、吸收性能好、制备工艺简单的蛋白钙产品。Chinese invention application patent (CN201510094700.6) discloses "a new type of calcium enhancer based on insoluble calcium and food-derived protein complex and its preparation and characterization method". Calcium is dispersed in water to form a suspension, and then mixed according to the mass ratio of protein and insoluble calcium of 2:1 to 1:200, the mixed solution after the reaction is separated by centrifugation or standing, and the obtained precipitate is rinsed and redispersed. Spray-drying or freeze-drying treatment to obtain insoluble calcium-protein composite powder. This method avoids the problems of poor product taste and high preparation cost caused by adding additional stabilizers to stabilize insoluble calcium salts, but it cannot meet the high utilization and high absorption of protein-bound calcium; moreover, it cannot achieve the effect of gradual release of calcium sources. The purpose of the present invention is to overcome the deficiencies of the prior art and develop a calcium protein product with safe raw materials, stable performance, high calcium content, good absorption performance and simple preparation process.
发明内容Contents of the invention
本发明的目的在于针对现有技术的不足之处,提供一种蛋白钙的制备方法,(1)将α-乳白蛋白溶解,配制蛋白溶液;The object of the present invention is to provide a method for preparing calcium proteinate in view of the deficiencies of the prior art, (1) dissolving α-lactalbumin to prepare protein solution;
(2)称取可溶性钙盐,配制钙溶液;(2) Take by weighing soluble calcium salt, prepare calcium solution;
(3)蛋白液与钙溶液混合,搅拌,形成含有结合钙的蛋白钙溶液;(3) The protein solution is mixed with the calcium solution and stirred to form a protein-calcium solution containing bound calcium;
(4)称取柠檬酸钙,加入上述反应液,搅拌、超声,使柠檬酸钙分散更充分,形成混悬液;(4) take calcium citrate, add above-mentioned reaction solution, stir, ultrasonic, make calcium citrate disperse more fully, form suspension;
(5)喷雾干燥,制备成粉。(5) Spray drying and preparing into powder.
进一步的,α-乳白蛋白溶液的质量浓度为2~30%(w/w),进一步的8~12%(w/w),进一步的10%(w/w)。Further, the mass concentration of the α-lactalbumin solution is 2-30% (w/w), further 8-12% (w/w), further 10% (w/w).
进一步的,可溶性钙盐为氯化钙或乳酸钙,例如L-乳酸钙。Further, the soluble calcium salt is calcium chloride or calcium lactate, such as L-calcium lactate.
进一步的,钙溶液的质量浓度为0.1~5%,进一步的0.5~1.5%,进一步的1%。Further, the mass concentration of the calcium solution is 0.1-5%, further 0.5-1.5%, and further 1%.
进一步的,蛋白液与钙溶液混合质量比为(1-5):(5:1),进一步的1:1。Further, the mixing mass ratio of protein solution and calcium solution is (1-5):(5:1), further 1:1.
进一步的,蛋白液与钙溶液混合搅拌条件为0~35℃,优选为10~30℃,进一步优先为20~25℃。Further, the stirring condition of protein liquid and calcium solution is 0-35°C, preferably 10-30°C, more preferably 20-25°C.
进一步的,蛋白液与钙溶液混合搅拌0.5min-2h,例如30min。Further, the protein solution and the calcium solution are mixed and stirred for 0.5min-2h, for example, 30min.
进一步的,柠檬酸钙和反应液的超声时间为,2min以上,例如,5min,10min,20min。Further, the ultrasonication time of the calcium citrate and the reaction solution is more than 2 minutes, for example, 5 minutes, 10 minutes, 20 minutes.
进一步的,喷雾干燥条件:进风温度185~195℃,出风温度80~90℃,蠕动速度10~50rpm。Further, spray drying conditions: air inlet temperature 185-195°C, air outlet temperature 80-90°C, creep speed 10-50rpm.
本发明还提供了一种蛋白钙,采用上述的方法进行制备而成。The present invention also provides protein calcium, which is prepared by the above-mentioned method.
本发明还提供了一种蛋白钙,含有α-乳白蛋白和钙的结合物,以及由α-乳白蛋白包裹的不溶性钙。The present invention also provides protein calcium, which contains a combination of α-lactalbumin and calcium, and insoluble calcium wrapped by α-lactalbumin.
进一步的,α-乳白蛋白包裹的不溶性钙为柠檬酸钙和/或碳酸钙。Further, the insoluble calcium encapsulated by α-lactalbumin is calcium citrate and/or calcium carbonate.
有益效果:Beneficial effect:
(1)一方面,由于产品同时具有蛋白结合钙和包裹的柠檬酸钙,提高了产物的钙含量,另一方面,外层壳结合钙量少但吸收利用较快,而内部包裹的柠檬酸钙钙量大释放吸收利用较慢,使得钙的吸收利用方面更加的平缓。(1) On the one hand, because the product has protein-bound calcium and encapsulated calcium citrate at the same time, the calcium content of the product is increased; The large amount of calcium releases and absorbs slowly, making the absorption and utilization of calcium more gentle.
(2)本发明选择出一种既能够包裹住不溶性钙,又同时能与钙离子结合的蛋白,并且制作步骤相对简单,使得生产方案和产物能够落地;达到了提高产品含钙量,以及平缓钙的吸收利用的两方面的效果。(2) The present invention selects a protein that can not only wrap insoluble calcium, but also combine with calcium ions, and the production steps are relatively simple, so that the production plan and products can be implemented; The absorption and utilization of calcium have two effects.
(3)外部包裹的结合钙壳相对于柠檬酸钙混悬液稳定性和分散性更好,提高了吸收利用的效果。(3) Compared with the calcium citrate suspension, the externally bound calcium shell has better stability and dispersibility, which improves the effect of absorption and utilization.
术语解释Terminology Explanation
α-乳白蛋白,即α-LA,含有一个紧密结合的Ca2+,强烈地影响着稳定性和结构;一些α-乳白蛋白为糖蛋白,载运单个、典型的连接聚糖一些的α—乳白蛋白,有较高比例的糖基化分子,应当理解为α-乳白蛋白,以及α-乳白蛋白的衍生物,都是在本专利保护范围之内。α-lactalbumin, or α-LA, contains a tightly bound Ca 2+ that strongly affects stability and structure; some α-lactalbumins are glycoproteins, carrying a single, typically linked glycan Some α-lactalbumin Proteins, which have a relatively high proportion of glycosylated molecules, should be understood as α-lactalbumin and derivatives of α-lactalbumin, which are all within the protection scope of this patent.
附图说明Description of drawings
图1为蛋白钙的粒径情况;Fig. 1 is the particle size situation of protein calcium;
图2为扫描电镜微观结构;Figure 2 is the scanning electron microscope microstructure;
图3为复溶后,得物稳定性情况。Figure 3 shows the stability of the product after reconstitution.
具体实施方式Detailed ways
为了便于本领域技术人员的理解,下面结合实施例对本发明作进一步的说明,实施方式提及的内容并非对本发明的限定。In order to facilitate the understanding of those skilled in the art, the present invention will be further described below in conjunction with the examples, and the contents mentioned in the embodiments are not intended to limit the present invention.
实施例1Example 1
称取10g的α-LA,溶解在90g水中,配制质量浓度10%(w/w)的蛋白溶液,同时,配制0.6%(w/w)的氯化钙(二水)溶液,二者等质量混合,室温搅拌1h。再称取8g柠檬酸钙粉末加入上述混合液中,搅拌、超声5min形成混悬液,经喷雾干燥成粉,得到的蛋白钙粉末呈白色,D50=7.78±0.25μm,扫描电镜的微观结构清晰,柠檬酸钙基本被包裹完整,为夹心钙结构。将0.25g蛋白钙粉末复水形成的悬浮液(2.5%,w/w),在室温下静置1h后,结果显示蛋白钙的稳定性明显比柠檬酸钙好。Weigh 10g of α-LA, dissolve it in 90g of water, prepare a protein solution with a mass concentration of 10% (w/w), and at the same time, prepare a 0.6% (w/w) calcium chloride (dihydrate) solution, the two, etc. The mass was mixed and stirred at room temperature for 1h. Then weigh 8g of calcium citrate powder and add it to the above mixed solution, stir and ultrasonic for 5 minutes to form a suspension, which is spray-dried into powder, and the obtained calcium protein powder is white, D 50 =7.78±0.25μm, the microstructure of scanning electron microscope Clear, the calcium citrate is basically wrapped completely, and it is a sandwich calcium structure. The suspension (2.5%, w/w) formed by rehydrating 0.25g of calcium protein powder was left to stand at room temperature for 1 hour, and the results showed that the stability of calcium proteinate was significantly better than that of calcium citrate.
实施例2Example 2
称取10g的α-LA,溶解在90g水中,配制质量浓度10%(w/w)的蛋白溶液,同时,配制1.25%(w/w)的L-乳酸钙(五水)溶液(0.6%的氯化钙(二水)和1.25%的乳酸钙(五水),钙含量相同),二者等质量混合,室温搅拌1h。再称取8g柠檬酸钙粉末加入上述混合液中,搅拌、超声5min形成混悬液,经喷雾干燥成粉,得到的蛋白钙粉末呈白色,流动性好,D50=6.79±0.05μm,扫描电镜在激发电压5kV、放大10000倍观察到的粉末颗粒结构清晰(见图2中第三张图),柠檬酸钙被包裹完整,为夹心钙结构。将0.25g粉末复水形成的悬浮液(2.5%,w/w),在室温下静置1h后显示,基本不分层,稳定性优于柠檬酸钙。Weigh the α-LA of 10g, be dissolved in 90g water, prepare the protein solution of
实施例3Example 3
称取10g的α-LA,溶解在90g水中,配制质量浓度10%(w/w)的蛋白溶液,同时,配制6%(w/w)的L-乳酸钙溶液,二者等质量混合,室温搅拌1h。再称取8g柠檬酸钙粉末加入上述混合液中,搅拌、超声5min形成混悬液,经喷雾干燥成粉,得到的蛋白钙粉末呈白色,D50=6.69±0.03μm,扫描电镜在激发电压5kV、放大10000倍观察到的粉末颗粒结构清晰(见图2第四张图),柠檬酸钙基本被包裹完整,为夹心钙结构。但颗粒不太完整,包裹效果不及实施例1和2。将0.25g粉末复水形成的悬浮液(2.5%,w/w),在室温下静置1h后有不明显分层。Weigh 10g of α-LA, dissolve it in 90g of water, prepare a protein solution with a mass concentration of 10% (w/w), and at the same time, prepare a 6% (w/w) L-calcium lactate solution, mix the two in equal mass, Stir at room temperature for 1 h. Then weigh 8g of calcium citrate powder and add it to the above mixed solution, stir and ultrasonic for 5min to form a suspension, and then spray-dry it into a powder. The powder particle structure observed at 5kV and 10,000 times magnification is clear (see the fourth picture in Figure 2), and the calcium citrate is basically completely wrapped, which is a sandwich calcium structure. But the particles are not complete, and the wrapping effect is not as good as that of Examples 1 and 2. The suspension (2.5%, w/w) formed by rehydrating 0.25 g of the powder had no obvious separation after standing at room temperature for 1 h.
实施例4Example 4
称取10g的α-LA,溶解在90g水中,配制质量浓度10%(w/w)的蛋白溶液,同时,配制1.25%(w/w)的L-乳酸钙溶液,二者等质量混合,室温搅拌1h。再称取12g柠檬酸钙粉末加入上述混合液中,搅拌、超声5min形成混悬液,经喷雾干燥成粉,得到的蛋白钙粉末呈白色,流动性好,D50=6.70±0.02μm,扫描电镜在激发电压5kV、放大10000倍观察到的粉末颗粒结构清晰(见图2第五张图),柠檬酸钙被包裹完整,为夹心钙结构。将0.25g粉末复水形成的悬浮液(2.5%,w/w),在室温下静置1h后无分层,稳定性较好,与实例2样品的“壳”相同,且含钙量较高。Weigh 10g of α-LA, dissolve it in 90g of water, prepare a protein solution with a mass concentration of 10% (w/w), and at the same time, prepare a 1.25% (w/w) L-calcium lactate solution, mix the two in equal mass, Stir at room temperature for 1 h. Then weigh 12g of calcium citrate powder and add it to the above mixture, stir and ultrasonic for 5min to form a suspension, and spray-dry to form a powder. The calcium protein powder obtained is white and has good fluidity. Electron microscope at an excitation voltage of 5kV and a magnification of 10,000 times observed a clear powder particle structure (see the fifth picture in Figure 2), and the calcium citrate was completely wrapped, which was a sandwich calcium structure. The suspension (2.5%, w/w) that 0.25g powder is rehydrated forms, after standing 1h at room temperature, there is no delamination, and the stability is better, the same as the "shell" of the example 2 sample, and the calcium content is higher high.
从图1可以看出,实施例1-4分别对应1-4,0为柠檬酸钙溶液混浊液相同条件下喷雾干燥的对照组。由D50可见,蛋白钙的粒径比柠檬酸钙溶液的粒径大很多;而蛋白钙之间的粒径存在差异,但差异并不大。As can be seen from Fig. 1, embodiments 1-4 correspond to 1-4 respectively, and 0 is the control group spray-dried under the same conditions of calcium citrate solution cloudy liquid. It can be seen from D 50 that the particle size of protein calcium is much larger than that of calcium citrate solution; and there are differences in particle size between protein calcium, but the difference is not large.
从图2可以看出,第一张图为柠檬酸钙溶液混浊液相同条件下喷雾干燥的对照组,实施例1-4分别对应图2中的第二到五张图。由图可知,蛋白钙粉末颗粒结构清晰,形成完整或者基本完整的壳儿,对柠檬酸钙能够起到包裹作用。As can be seen from Figure 2, the first picture is the control group spray-dried under the same conditions as the calcium citrate solution turbid liquid, and embodiments 1-4 correspond to the second to fifth pictures in Figure 2 respectively. It can be seen from the figure that the calcium protein powder has a clear particle structure and forms a complete or basically complete shell, which can wrap calcium citrate.
从图3可以看出,蛋白钙复溶后基本不分层或者有不明显的分层,而柠檬酸钙很快形成沉淀。It can be seen from Figure 3 that there is basically no or no obvious layering after reconstitution of calcium proteinate, while calcium citrate quickly forms a precipitate.
本技术领域技术人员可以理解,除非另外定义,这里使用的所有术语(包括技术术语和科学术语),具有与本发明所属领域中的普通技术人员的一般理解相同的意义。还应该理解的是,诸如通用字典中定义的那些术语,应该被理解为具有与现有技术的上下文中的意义一致的意义,并且除非像这里一样被特定定义,否则不会用理想化或过于正式的含义来解释。Those skilled in the art can understand that, unless otherwise defined, all terms (including technical terms and scientific terms) used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this invention belongs. It should also be understood that terms, such as those defined in commonly used dictionaries, should be understood to have meanings consistent with their meaning in the context of the prior art, and unless specifically defined as herein, are not intended to be idealized or overly Formal meaning to explain.
应当理解,以上借助优选实施例对本发明的技术方案进行的详细说明是示意性的而非限制性的。本领域的普通技术人员在阅读本发明说明书的基础上可以对各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的精神和范围。It should be understood that the above detailed description of the technical solution of the present invention with the aid of preferred embodiments is illustrative rather than restrictive. Those skilled in the art can modify the technical solutions recorded in each embodiment on the basis of reading the description of the present invention, or perform equivalent replacements for some of the technical features; and these modifications or replacements do not make the corresponding technical solutions Essentially deviate from the spirit and scope of the technical solutions of the various embodiments of the present invention.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310334569.0A CN116326782A (en) | 2023-03-31 | 2023-03-31 | Protein calcium and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310334569.0A CN116326782A (en) | 2023-03-31 | 2023-03-31 | Protein calcium and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116326782A true CN116326782A (en) | 2023-06-27 |
Family
ID=86877066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310334569.0A Pending CN116326782A (en) | 2023-03-31 | 2023-03-31 | Protein calcium and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116326782A (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766330A (en) * | 1996-12-24 | 1998-06-16 | Knights; Ralph J. | Method of suspending insoluble calcium in protein composition |
WO2000045650A1 (en) * | 1999-02-06 | 2000-08-10 | Nutrahealth Ltd. (Uk) | Calcium supplemented food products and novel calcium-containing ingredient |
CN104738649A (en) * | 2015-03-03 | 2015-07-01 | 江南大学 | Novel calcium enhancer based on poorly-soluble calcium and food-borne protein complexes as well as preparation method and characterization method thereof |
CN106343579A (en) * | 2016-08-30 | 2017-01-25 | 雷春生 | Fish bladder collagen small peptide chelate calcium and preparing method thereof |
CN107549801A (en) * | 2017-08-24 | 2018-01-09 | 福格森(武汉)生物科技股份有限公司 | A kind of multilayer embeds solid lipid calcium particulate |
CN110604213A (en) * | 2019-09-09 | 2019-12-24 | 苏州恒瑞健康科技有限公司 | Process method for improving protein stability |
CN113813362A (en) * | 2021-09-27 | 2021-12-21 | 山东安为先生物科技有限公司 | Stable small peptide chelated calcium, preparation method and application |
CN114401639A (en) * | 2019-09-16 | 2022-04-26 | 雀巢产品有限公司 | Whey-based nutritional composition fortified with calcium |
US20220386674A1 (en) * | 2019-11-13 | 2022-12-08 | Societe Des Produits Nestle S.A. | Use of alpha-lactalbumin enriched whey protein extract as a source of cholesterol |
-
2023
- 2023-03-31 CN CN202310334569.0A patent/CN116326782A/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766330A (en) * | 1996-12-24 | 1998-06-16 | Knights; Ralph J. | Method of suspending insoluble calcium in protein composition |
WO2000045650A1 (en) * | 1999-02-06 | 2000-08-10 | Nutrahealth Ltd. (Uk) | Calcium supplemented food products and novel calcium-containing ingredient |
CN104738649A (en) * | 2015-03-03 | 2015-07-01 | 江南大学 | Novel calcium enhancer based on poorly-soluble calcium and food-borne protein complexes as well as preparation method and characterization method thereof |
CN106343579A (en) * | 2016-08-30 | 2017-01-25 | 雷春生 | Fish bladder collagen small peptide chelate calcium and preparing method thereof |
CN107549801A (en) * | 2017-08-24 | 2018-01-09 | 福格森(武汉)生物科技股份有限公司 | A kind of multilayer embeds solid lipid calcium particulate |
CN110604213A (en) * | 2019-09-09 | 2019-12-24 | 苏州恒瑞健康科技有限公司 | Process method for improving protein stability |
CN114401639A (en) * | 2019-09-16 | 2022-04-26 | 雀巢产品有限公司 | Whey-based nutritional composition fortified with calcium |
US20220378064A1 (en) * | 2019-09-16 | 2022-12-01 | Societe Des Produits Nestle S.A. | Whey-based nutritional compositions fortified with calcium |
US20220386674A1 (en) * | 2019-11-13 | 2022-12-08 | Societe Des Produits Nestle S.A. | Use of alpha-lactalbumin enriched whey protein extract as a source of cholesterol |
CN113813362A (en) * | 2021-09-27 | 2021-12-21 | 山东安为先生物科技有限公司 | Stable small peptide chelated calcium, preparation method and application |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112042937B (en) | Water-soluble lutein emulsion gel and preparation method thereof | |
CN105054073B (en) | A kind of water miscible vitamine D3 nano particle and preparation method thereof | |
CN110679953A (en) | Preparation method of nano liposome embedded with egg white source active peptide | |
CN108484715A (en) | A kind of protein binding type nanometer selenium and its preparation method and application | |
CN107496359A (en) | The preparation method of PluronicF127 curcumin liposomes | |
CN110367410A (en) | A kind of compound lactobacillus fruit drink and preparation method thereof | |
CN116326782A (en) | Protein calcium and preparation method thereof | |
KR100871050B1 (en) | Preparation method of microcapsules containing coenzyme q-ten | |
CN114651989A (en) | Donkey-hide gelatin peptide-iron chelate microcapsule and preparation method thereof | |
CN113875979A (en) | A kind of preparation method of food-grade oil-water dual-phase loaded emulsion gel carrier system | |
CN117099849A (en) | Pure goat milk protein formula goat milk powder and preparation method thereof | |
CN115886255B (en) | A high-stability blueberry anthocyanin binary gel tablet and preparation method thereof | |
AU2021103800A4 (en) | Controlled-Released Lutein Emulsion Gel and Formulation Thereof | |
CN110496227A (en) | A clarified hydrophobic polyphenol delivery system based on oat β-glucan and its preparation method | |
CN116870171A (en) | Oyster-source exosome-like vesicle and preparation method and application thereof | |
CN116509800A (en) | Method and Application of Enhancing the Stability of Micron Calcium Carbonate Pickering Emulsion | |
CN114601170A (en) | New method for dissolving heme | |
CN114431482A (en) | Nano gel, preparation method and beverage reinforced by nano gel | |
CN105596377A (en) | Cyclodextrin-Auricularia auricula micropowder combination and preparation method and preparation thereof | |
CN115606800B (en) | Construction method of high-stability high-load glycosylated protein fiber nano delivery system | |
CN116268106B (en) | Dairy product and preparation method thereof | |
CN107582524A (en) | The preparation method of PluronicF87 curcumin liposomes | |
CN107865444A (en) | A kind of preparation method of nanogel | |
CN119969566A (en) | Preparation method of soybean protein isolate/κ-carrageenan composite gel loaded with VD3 | |
CN118526471A (en) | Double-targeting nanoparticle and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |